早产儿支气管肺发育不良的表型演变

丁瑛雪

doi:10.12372/jcp.2022.22e0360

临床儿科杂志 >

2022 , Vol. 40 >Issue 6: 407 - 412

DOI: https://doi.org/10.12372/jcp.2022.22e0360

专家笔谈

早产儿支气管肺发育不良的表型演变

丁瑛雪

展开

首都医科大学附属北京友谊医院（北京 100050）

丁瑛雪（1976—）,博士,ORCID：0000-0002-1386-7987,青年编委,首都医科大学附属北京友谊医院儿科副主任,博士,主任医师。目前临床研究方向主要是新生儿神经发育。在国家自然科学基金青年基金、北京市优秀人才培养资助项目的支持下,探讨宫内生长受限患儿脑损伤机制及早期干预可能。申请发明专利1项,近5年第一作者/通讯作者发表SCI论文10余篇。荣获2016-2017年度全国十大妇幼天使。兼任中国医药教育协会新生儿专委会副主任委员,中国中西医结合学会儿科专业委员会常务委员,中国研究型医院儿科分会青年委员,中国医师协会新生儿科医师分会专业协同委员会委员,北京医师协会儿科专家委员会理事,北京医师协会儿科神经专家委员会委员等。

收稿日期: 2022-03-13

网络出版日期: 2022-06-07

收起

Phenotypic evolution of bronchopulmonary dysplasia in premature infants

Yingxue DING

Expand

Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received date: 2022-03-13

Online published: 2022-06-07

Fold

摘要

支气管肺发育不良（bronchopulmonary dysplasia,BPD）是早产儿最常见的慢性肺部疾病,与婴儿死亡率、呼吸系统发病率增加有关。随着新生儿重症医学取得进展的同时,BPD的表型已从主要影响晚期早产儿、肺纤维囊性变演变为主要影响胎龄小于28周的超早产儿、肺实质受损和血管生长失调。文章评估了BPD定义演变、病理生理演变、影像演变及临床表型的演变特点,以期寻找新的循证预防和管理策略,改善疾病表型分类,早期识别高危早产儿的临床特点,以改善其预后。

关键词： 早产儿; 支气管肺发育不良; 表型

本文引用格式

丁瑛雪 . 早产儿支气管肺发育不良的表型演变[J]. 临床儿科杂志, 2022 , 40(6) : 407 -412 . DOI: 10.12372/jcp.2022.22e0360

Abstract

Bronchopulmonary dysplasia (BPD) is the commonest chronic lung disease in preterm infants, and is associated with increased infant mortality and respiratory incidence rate. With the progress of neonatal intensive care medicine, the phenotype of BPD has evolved from fibrocystic disease affecting late preterm infants to lung parenchyma damage and vascular growth disorder mainly affecting infants born 28 weeks ago. In this article, we evaluated the evolution of the definition, pathophysiology, imaging and clinical phenotypes of BPD in order to find new evidence-based prevention and management strategies, to improve the classification of disease phenotypes, to early identify the clinical characteristics of high-risk premature infants and improve their prognosis.

Key words： preterm infants; bronchopulmonary dysplasia; phenotype

参考文献

[1]	Bancalari E, Jain D. Bronchopulmonary dysplasia: 50 years after the original description[J]. Neonatology, 2019, 115(4): 384-391.
[2]	Thébaud B, Goss KN, Laughon M, et al. Broncho-pulmonary dysplasia[J]. Nat Rev Dis Primers, 2019, 5(1): 78.
[3]	Gilfillan M, Bhandari A, Bhandari V. Diagnosis and management of bronchopulmonary dysplasia[J]. BMJ, 2021, 375: n1974.
[4]	Jiang S, Yan W, Li S, et al. Mortality and morbidity in infants< 34 weeks' gestation in 25 NICUs in China: a prospective cohort study[J]. Front Pediatr, 2020, 8: 33.
[5]	Lapcharoensap W, Gage SC, Kan P, et al. Hospital variation and risk factors for bronchopulmonary dysplasia in a population-based cohort[J]. JAMA Pediatr, 2015, 169(2): e143676.
[6]	Tracy MK, Berkelhamer SK. Bronchopulmonary dysplasia and pulmonary outcomes of prematurity[J]. Pediatr Ann, 2019, 48(4): e148-e153.
[7]	Collaco JM, McGrath-Morrow SA. Bronchopulmonary dysplasia as a determinant of respiratory outcomes in adult life[J]. Pediatr Pulmonol, 2021, 56(11): 3464-3471.
[8]	Humayun J, Löfqvist C, Ley D, et al. Systematic review of the healthcare cost of bronchopulmonary dysplasia[J]. BMJ Open, 2021, 11(8): e045729.
[9]	Bancalari E, Jain D. Bronchopulmonary dysplasia: can we agree on a definition?[J]. Am J Perinatol, 2018, 35(6): 537-540.
[10]	Jensen EA, Dysart K, Gantz MG, et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. an evidence-based approach[J]. Am J Respir Crit Care Med, 2019, 200(6): 751-759.
[11]	Hwang JS, Rehan VK. Recent advances in bronchopulmonary dysplasia: pathophysiology, prevention, and treatment[J]. Lung, 2018, 196(2): 129-138.
[12]	Gallini F, Coppola M, De Rose DU, et al. Neurodevelopmental outcomes in very preterm infants: the role of severity of bronchopulmonary dysplasia[J]. Early Hum Dev, 2021, 152: 105275.
[13]	Principi N, Di Pietro GM, Esposito S. Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies[J]. J Transl Med, 2018, 16(1): 36.
[14]	Allen J, Panitch H. Bronchopulmonary dysplasia-A historical perspective[J]. Pediatr Pulmonol, 2021, 56(11): 3478-3489.
[15]	Voynow JA. "New" bronchopulmonary dysplasia and chronic lung disease[J]. Paediatr Respir Rev, 2017, 24: 17-18.
[16]	Alvira CM, Morty RE. Can we understand the pathobiology of bronchopulmonary dysplasia?[J]. J Pediatr, 2017, 190: 27-37.
[17]	Walkup LL, Woods JC. Newer imaging techniques for bronchopulmonary dysplasia[J]. Clin Perinatol, 2015, 42(4): 871-887.
[18]	Li R, Zhang J. Diagnostic value of chest CT combined with X-ray for premature infants with bronchopulmonary dysplasia[J]. Medicine (Baltimore), 2018, 97(9): e9723.
[19]	Higano NS, Ruoss JL, Woods JC. Modern pulmonary imaging of bronchopulmonary dysplasia[J]. J Perinatol, 2021, 41(4): 707-717.
[20]	Voskrebenzev A, Vogel-Claussen J. Proton MRI of the lung: how to tame scarce protons and fast signal decay[J]. J Magn Reson Imaging, 2021, 53(5): 1344-1357.
[21]	Loi B, Vigo G, Baraldi E, et al. Lung ultrasound to monitor extremely preterm infants and predict bronchopulmonary dysplasia. a multicenter longitudinal cohort study[J]. Am J Respir Crit Care Med, 2021, 203(11): 1398-1409.
[22]	Alonso-Ojembarrena A, Lubián-López SP. Lung ultrasound score as early predictor of bronchopulmonary dysplasia in very low birth weight infants[J]. Pediatr Pulmonol, 2019, 54(9) : 1404-1409.
[23]	刘敬. 肺脏超声对早产儿支气管肺发育不良的预测及诊断价值[J]. 江苏大学学报, 2022, 32(2): 1-4.
[24]	Wang SH, Tsao PN. Phenotypes of bronchopulmonary dysplasia[J]. Int J Mol Sci, 2020, 21(17): 6112.
[25]	Higgins RD, Jobe AH, Koso-Thomas M, et al. Broncho-pulmonary dysplasia: executive summary of a workshop[J]. J Pediatr, 2018, 197: 300-308.
[26]	Glaser K, Gradzka-Luczewska A, Szymankiewicz-Breborowicz M, et al. Perinatal ureaplasma exposure is associated with increased risk of late onset sepsis and imbalanced inflammation in preterm infants and may add to lung injury[J]. Front Cell Infect Microbiol, 2019, 9: 68.
[27]	Viscardi RM, Kallapur SG. Role of ureaplasma respiratory tract colonization in bronchopulmonary dysplasia pathogenesis: current concepts and update[J]. Clin Perinatol, 2015, 42(4): 719-738.
[28]	Viscardi RM, Terrin ML, Magder LS, et al. Randomised trial of azithromycin to eradicate ureaplasma in preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2020, 105(6): 615-622.
[29]	Wang J, Dong W. Oxidative stress and bronchopulmonary dysplasia[J]. Gene, 2018, 678: 177-183.
[30]	余彦亮, 邹新英, 杨传忠. 超未成熟儿支气管肺发育不良临床特点、治疗及预后分析[J]. 临床儿科杂志, 2019, 37(1): 11-15.
[31]	Collins A. Stem-cell therapy for bronchopulmonary dysplasia[J]. Curr Opin Pediatr, 2020, 32(2): 210-215.
[32]	Li JY, Lin ZL, Wei J, et al. What is the optimal oxygen saturation for extremely premature infants? a meta analysis[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2015, 17(2): 128-133.
[33]	Ramaswamy VV, Bandyopadhyay T, Nanda D, et al. Assessment of postnatal corticosteroids for the prevention of bronchopulmonary dysplasia in preterm neonates: a systematic review and network meta-analysis[J]. JAMA Pediatr, 2021, 175(6): e206826.
[34]	Filippone M, Nardo D, Bonadies L, et al. Update on postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia[J]. Am J Perinatol, 2019, 36(S02):S58-S62.
[35]	Delara M, Chauhan BF, Le ML, et al. Efficacy and safety of pulmonary application of corticosteroids in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis[J]. Arch Dis Child Fetal Neonatal Ed, 2019, 104: F137-F144.
[36]	Herting E, Härtel C, Göpel W. Less invasive surfactant administration (LISA): chances and limitations[J]. Arch Dis Child Fetal Neonatal Ed, 2019, 104(6): F655-F659.
[37]	Gupta BK, Saha AK, Mukherjee S, et al. Minimally invasive surfactant therapy versus InSurE in preterm neonates of 28 to 34 weeks with respiratory distress syndrome on non-invasive positive pressure ventilation-a randomized controlled trial[J]. Eur J Pediatr, 2020, 179(8): 1287-1293.
[38]	DeMauro SB. Neurodevelopmental outcomes of infants with bronchopulmonary dysplasia[J]. Pediatr Pulmonol, 2021, 56(11): 3509-3517.
[39]	Dekker J, Hooper SB, van Vonderen JJ, et al. Caffeine to improve breathing effort of preterm infants at birth: a randomized controlled trial[J]. Pediatr Res, 2017, 82(2): 290-296.
[40]	Moschino L, Zivanovic S, Hartley C, et al. Caffeine in preterm infants: where are we in 2020?[J]. ERJ Open Res, 2020, 6(1): 00330-2019.
[41]	Mandell EW, Kratimenos P, Abman SH, et al. Drugs for the prevention and treatment of bronchopulmonary dysplasia[J]. Clin Perinatol, 2019, 46(2): 291-310.
[42]	Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease[J]. Cochrane Database Syst Rev, 2011, 2011(9): CD001817.
[43]	Euteneuer JC, Kerns E, Leiting C, et al. Inhaled bronchodilator exposure in the management of bronchopulmonary dysplasia in hospitalized infants[J]. J Perinatol, 2021, 41(1): 53-61.
[44]	Rakshasbhuvankar AA, Simmer K, Patole SK, et al. Enteral vitamin A for reducing severity of bronchopulmonary dysplasia: a randomized trial[J]. Pediatrics, 2021, 147(1): e2020009985.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献